Consumer drug behemoth Reckitt is dropping $600 million on a multi-year revamp of its U.S. operations.
The health and hygiene conglomerate, known for brands like Lysol and Mucinex, will spend the funds building out an R&D hub at its new headquarters and finalizing the largest of its seven manufacturing sites by 50%.
Reckitt made its manufacturing expansion plans known back in 2024, announcing a $145 million regional manufacturing center in Wilson, North Carolina, that would increase production capacity for Mucinex products among other OTC drugs. The plant is now set to open in the first half of 2027, and Reckitt has doubled its initial investment in the facility, according to a statement by the company.
The site will become the largest of the company’s U.S. manufacturing sites, reinforcing the domestic Mucinex supply chain while leaving space for flexibility as consumer demand evolves.
As the manufacturing expansion is wrapping up, Reckitt is set to break ground on new projects in New Jersey. At its new U.S. headquarters, the OTC titan has plans for an innovation center that the company called a “flagship germ protection hub” with capabilities in disinfection, microbiology, surface care, laundry care and personal care.
Adding the new research center to its North American campus will bring Reckitt’s innovation arm onsite with its commercial center which the company says is pivotal to advancing its portfolio.
Angela Naef, Ph.D., chief R&D officer at Reckitt, said, “This investment fundamentally changes how we innovate. By bringing science, insight and execution closer together, we can move faster from discovery to delivery, developing high-quality, science-led solutions that meet evolving consumer needs and scale globally.”